Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing a combination of epacadostat plus pembrolizumab in 62 patients with advanced solid tumours shows objective responses in 12 of 22 patients (55%) with melanoma and in patients with other solid tumours, such as renal cell carcinoma (RCC). Severe and life-threatening side effects were reported by almost a quarter of patients.

Epacadostat is a potent and highly selective IDO1 enzyme inhibitor and pembrolizumab is a PD-1 inhibitor.

The researchers conclude that epacadostat in combination with pembrolizumab offers promising anti-tumour activity with an acceptable safety profile in multiple advanced solid tumours, including RCC.

Read more in Practice Update here